362 related articles for article (PubMed ID: 7349093)
21. [Assays in delayed hypersensitivity in the course of Hodgkin's disease].
Bernadou A; Zittoun R; Blanc CM; Smadja R; Bousser J
Ann Med Interne (Paris); 1970 Mar; 121(3):301-11. PubMed ID: 5507504
[No Abstract] [Full Text] [Related]
22. [The importance of nonspecific immunotherapy in Hodgkin's disease. Experience of the first comprehensive control team in the Department of General Medicine at Charles University in Prague].
Dienstbier Z; Foltýnová V; Citavý M
Cas Lek Cesk; 1986 Apr; 125(17):518-23. PubMed ID: 3521864
[No Abstract] [Full Text] [Related]
23. [Immunotherapy of carcinoma of the lung].
Sega E; Mineo TC; Rea SR; Sega FM; Ricci C
Recenti Prog Med; 1978 Mar; 64(3):293-309. PubMed ID: 351751
[No Abstract] [Full Text] [Related]
24. [E-RFC (T cells) and Ig-positive cells (B cells) in the peripheral blood of patients with lymphogranulomatosis and possible immunocorrection with levamisole].
Markova TP; Danilova NV
Ter Arkh; 1985; 57(7):15-8. PubMed ID: 3876611
[TBL] [Abstract][Full Text] [Related]
25. Immune condition in patients with Hodgkin's disease.
Zywicka-Lopaciuk H; Konopka L; Traczyk Z; Pawelski S; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Karpowicz M; Małkowska-Zwierz W
Arch Immunol Ther Exp (Warsz); 1980; 28(1):153-60. PubMed ID: 6968189
[TBL] [Abstract][Full Text] [Related]
26. Use of BCG or levamisole as an adjunct to chemotherapy or radiotherapy in malignant lymphomas.
Advani SH; Gangal SG; Gopal R; Nair CN; Dinshaw KA; Desai PB
Indian J Med Res; 1985 Mar; 81():306-12. PubMed ID: 4018861
[No Abstract] [Full Text] [Related]
27. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta.
Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754
[TBL] [Abstract][Full Text] [Related]
28. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
Land JM; Litwin J; Bigel P; Oberling F; Mayer S
Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
[TBL] [Abstract][Full Text] [Related]
29. [Immunologic studies in Hodgkin's disease].
Amiel JL; Schneider M
Bull Cancer; 1971; 58(1):9-20. PubMed ID: 5564288
[No Abstract] [Full Text] [Related]
30. [Studies of monocytopoiesis in patients with malignant disease and after immunostimulation with BCG, using 3H-thymidine as a DNA-label (author's transl)].
Schmitt E; Meuret G; Waldermann F; Hoffmann G
Nuklearmedizin; 1982 Apr; 21(2):49-54. PubMed ID: 7099973
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant immunotherapy after surgery and radiotherapy for breast carcinoma.
Papavasiliou C; Pappas J; Pavlatou M; Keramopoulos A; Giannakoulis N; Koumantakis E; Nicolaïdis C
Strahlentherapie; 1982 Apr; 158(4):206-9. PubMed ID: 7101333
[No Abstract] [Full Text] [Related]
32. Spleen lymphocyte populations in patients with Hodgkin's disease--properties of cells with different densities.
Rocha B; Ferreira AA; Munn G; de Sousa M; Freitas AA
Clin Exp Immunol; 1982 May; 48(2):300-6. PubMed ID: 7105487
[TBL] [Abstract][Full Text] [Related]
33. Effect of thymus factor and levamisole treatment in patients with persistent nephrotic syndrome.
Czekalski S; Sulima D; Strzelecka G
Proc Eur Dial Transplant Assoc; 1983; 19():800-3. PubMed ID: 6603617
[TBL] [Abstract][Full Text] [Related]
34. [Immunological data in the clinical evaluation of Hodgkin's diseases].
Burchardt K
Z Gesamte Inn Med; 1981 Nov; 36(21):840. PubMed ID: 6977241
[TBL] [Abstract][Full Text] [Related]
35. The in vivo and in vitro effects of levamisole in patients with lepromatous leprosy.
Sher R; Wadee AA; Joffe M; Kok SH; Imkamp FM; Simson IW
Int J Lepr Other Mycobact Dis; 1981 Jun; 49(2):159-66. PubMed ID: 7196885
[TBL] [Abstract][Full Text] [Related]
36. [Present evaluation of hansenian treatment by association of chemotherapy and immunostimulation (author's transl)].
Saint-Andre P; Louvet M; Giraudeau P; Discamps G; Schlecht B
Med Trop (Mars); 1978; 38(3):331-49. PubMed ID: 723581
[TBL] [Abstract][Full Text] [Related]
37. Autologous rosette-forming capacity of T-lymphocytes in Hodgkin's disease.
Bodolay E; Berényi E; Sonkoly I; Szegedi G
Acta Med Hung; 1984; 41(2-3):113-9. PubMed ID: 6611543
[TBL] [Abstract][Full Text] [Related]
38. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
[TBL] [Abstract][Full Text] [Related]
39. [The late results of the combined treatment of kidney cancer patients].
Mavrichev AS; Grigorovich NA; Sukonko OG; Rovbut' II
Urol Nefrol (Mosk); 1990; (5):13-6. PubMed ID: 2264198
[TBL] [Abstract][Full Text] [Related]
40. Responses to tests of cell mediated immunity before, during and after BCG administration in Hodgkin's disease.
Lenzini L; Bracci R; Rottoli P; Rottoli L
Boll Ist Sieroter Milan; 1974; 53(1):suppl:300. PubMed ID: 4546904
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
